Summary
For Year 2026-27, CORONA Remedies reports the following shareholding: Total Promoters at 69%, Mutual Fund at 6.38%, Insurance at 0.34%, Foreign Institutional Investors at 1.84%, Domestic Institutional Investors at 0.04%, and Retail at 22.4%. This breakdown provides a quick snapshot of ownership distribution for CORONA Remedies in 2026-27.
CORONA Remedies FAQs
As of 04-2026, the promoter shareholding in CORONA Remedies stands at 69% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of CORONA Remedies is 1.84% and 0.04% respectively.
The retail shareholding of the CORONA Remedies is 22.4%.
Changes in shareholding patterns of CORONA Remedies can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of CORONA Remedies are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
